Skip to main content
Caplight Logo









Nkure Therapeutics

Nkure Therapeutics

Private
Bangalore UrbanHealthcare & Life Scienceshttps://www.nkure.com/

Last Round

Pre Seed

Apr 26, 2023

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Nkure Therapeutics is a biotechnology company developing affordable natural killer (NK) cell-based immunotherapies for cancer and infectious diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

natural killer cell therapyNK cell therapyallogeneic cell therapyoff-the-shelf therapycell-based immunotherapygene-edited cellsoncology biotechcancer immunotherapyhematological malignanciessolid tumor treatmentpreclinical drug developmentoff-the-shelf medicinenext-gen immunotherapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nkure Therapeutics Comparables

Compare Nkure Therapeutics with similar companies based on industry and business-model similarity.

Nkure Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Century Therapeutics
75%
Artiva
74%
Wugen
73%

Nkure Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Pre SeedApr 26, 2023

Nkure Therapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 22, 2026

    Grew 25% QoQ, from 12 to 15 employees.

  • Aug 21, 2026

    Monthly visitors grew 470% MoM to 1.2K.

Recent news

Latest coverage and updates

  • receives_financingAug 31, 2026

    NKure Therapeutics Pvt. Ltd. receives financing of $2.15M.

Nkure Therapeutics Filings

Explore SEC and related filing metadata, where available.

Nkure Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Nkure Therapeutics's valuation, stock price, and market status.

Is Nkure Therapeutics a public or private company?

Nkure Therapeutics is a private company.

What is the current stock price of Nkure Therapeutics?

Nkure Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Nkure Therapeutics worth (valuation)?

Valuation information for Nkure Therapeutics is not publicly available.

Can I buy Nkure Therapeutics stock?

Nkure Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Nkure Therapeutics's last funding round?

Nkure Therapeutics's most recent funding round was Seed on April 26, 2023.

Who are the main investors in Nkure Therapeutics?

Key investors in Nkure Therapeutics include Endiya Partners, Innovative Quest Private Limited, Kotak Alternate Asset Managers.

Will Nkure Therapeutics IPO soon?

No public IPO plans have been announced for Nkure Therapeutics.

How can I track Nkure Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Nkure Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBangalore Urban
Employee Range12
Year Founded2021
Last FundingApr 26, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?